BCA
TEVA icon

Bray Capital Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Bray Capital Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-331
Closed -$20K – 428
2015
Q2 		$20K Buy
+331
New +$20.4K 0.01% 291

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bray Capital Advisors's TEVA Position: Q3 2015 in Review

Bray Capital Advisors sold out of Teva Pharmaceuticals (TEVA) in Q3 2015, closing a stake of 331 shares — an estimated $20K sold.

Bray Capital Advisors first reported a position in TEVA in Q2 2015 and held it in 1 quarter. The position peaked at $20K in Q2 2015. 823 funds tracked by Wall St. Rank hold TEVA as of Q3 2015.

  • Bray Capital Advisors reported no remaining Teva Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Bray Capital Advisors sold 331 Teva Pharmaceuticals shares in Q3 2015, an estimated $20K.
  • Bray Capital Advisors first reported a position in Teva Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • Bray Capital Advisors's Teva Pharmaceuticals position peaked at $20K in Q2 2015.
  • 823 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2015.

Based on Bray Capital Advisors's 13F filing for Q3 2015, filed 27 Oct 2015.